Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
Axogen (AXGN) will release its third-quarter 2026 financial results on October 28, 2026, followed by a management conference call.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Axogen (AXGN) will release its third-quarter 2026 financial results on October 28, 2026, followed by a management conference call.
The investment-community call and webcast will begin at 8:00 a.m. ET. A live webcast, archived replay and presentation slides will be available on the Investors page at www.axogeninc.com.
Key Figures
- Results release date
- October 28, 2026
- Third quarter 2026 financial results
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALACHUA, Fla. and TAMPA, Fla., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the third quarter of 2026 on Wednesday, October 28, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available on the Investors page of the company's website at www.axogeninc.com.
About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, Avive+ Soft Tissue Matrix™, and NerveTape™.
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
